The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
作者信息
Uddin Mohib, Betts Catherine, Robinson Ian, Malmgren Anna, Humfrey Charles
机构信息
The IMED Respiratory, Inflammation & Autoimmunity Unit, AstraZeneca Gothenburg, Mölndal, Sweden.
Drug Safety and Metabolism, AstraZeneca R&D, Cambridge, U.K.
出版信息
Haematologica. 2017 Feb;102(2):e65-e68. doi: 10.3324/haematol.2016.152371. Epub 2016 Oct 14.
Abstract
摘要
相似文献
1
The chemokine CXCR2 antagonist (AZD5069) preserves neutrophil-mediated host immunity in non-human primates.
Haematologica. 2017 Feb;102(2):e65-e68. doi: 10.3324/haematol.2016.152371. Epub 2016 Oct 14.
2
The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Br J Clin Pharmacol. 2015 Dec;80(6):1324-36. doi: 10.1111/bcp.12724. Epub 2015 Oct 2.
3
Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
J Pharmacol Exp Ther. 2015 May;353(2):340-50. doi: 10.1124/jpet.114.221358. Epub 2015 Mar 3.
4
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4.
5
Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.
Pulm Pharmacol Ther. 2017 Aug;45:121-123. doi: 10.1016/j.pupt.2017.05.012. Epub 2017 May 23.
6
The development and characterization of an in vitro model of psoriasis.
J Invest Dermatol. 2004 Nov;123(5):892-901. doi: 10.1111/j.0022-202X.2004.23435.x.
7
Modulation of Human Macrophage Responses to Mycobacterium tuberculosis by Silver Nanoparticles of Different Size and Surface Modification.
PLoS One. 2015 Nov 18;10(11):e0143077. doi: 10.1371/journal.pone.0143077. eCollection 2015.
8
The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.
Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.
9
Chemokine CXCL1-Mediated Neutrophil Trafficking in the Lung: Role of CXCR2 Activation.
J Innate Immun. 2015;7(6):647-58. doi: 10.1159/000430914. Epub 2015 Jul 1.
10
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans.
Br J Clin Pharmacol. 2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x.
引用本文的文献
1
Targeting CXCR2 signaling in inflammatory lung diseases: neutrophil-driven inflammation and emerging therapies.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 6. doi: 10.1007/s00210-025-03970-x.
2
Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.
J Endocrinol Invest. 2025 Jan;48(1):53-65. doi: 10.1007/s40618-024-02410-6. Epub 2024 Jun 20.
3
CXCR2 Antagonist RIST4721 Acts as a Potent Chemotaxis Inhibitor of Mature Neutrophils Derived from Ex Vivo-Cultured Mouse Bone Marrow.
Biomedicines. 2023 Feb 7;11(2):479. doi: 10.3390/biomedicines11020479.
4
The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials.
Front Immunol. 2022 Jul 25;13:932251. doi: 10.3389/fimmu.2022.932251. eCollection 2022.
5
CXCR2 Mediates Distinct Neutrophil Behavior in Brain Metastatic Breast Tumor.
Cancers (Basel). 2022 Jan 20;14(3):515. doi: 10.3390/cancers14030515.
6
Neutrophilia and NETopathy as Key Pathologic Drivers of Progressive Lung Impairment in Patients With COVID-19.
Front Pharmacol. 2020 Jun 5;11:870. doi: 10.3389/fphar.2020.00870. eCollection 2020.
7
Distinct Spatio-Temporal Dynamics of Tumor-Associated Neutrophils in Small Tumor Lesions.
Front Immunol. 2019 Jun 25;10:1419. doi: 10.3389/fimmu.2019.01419. eCollection 2019.
8
NETopathic Inflammation in Chronic Obstructive Pulmonary Disease and Severe Asthma.
Front Immunol. 2019 Feb 5;10:47. doi: 10.3389/fimmu.2019.00047. eCollection 2019.
9
The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics.
Curr Opin Hematol. 2019 Jan;26(1):28-33. doi: 10.1097/MOH.0000000000000476.
10
Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.
J Immunol Res. 2017;2017:5273201. doi: 10.1155/2017/5273201. Epub 2017 May 15.
本文引用的文献
1
A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4.
2
The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Br J Clin Pharmacol. 2015 Dec;80(6):1324-36. doi: 10.1111/bcp.12724. Epub 2015 Oct 2.
3
Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype?
J Leukoc Biol. 2015 Oct;98(4):549-56. doi: 10.1189/jlb.3VMR1214-600RR. Epub 2015 May 14.
4
Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
J Pharmacol Exp Ther. 2015 May;353(2):340-50. doi: 10.1124/jpet.114.221358. Epub 2015 Mar 3.
5
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med. 2015 May 1;191(9):1001-11. doi: 10.1164/rccm.201405-0992OC.
6
Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.
J Cyst Fibros. 2013 May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17.
7
Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial.
Clin Exp Allergy. 2012 Jul;42(7):1097-103. doi: 10.1111/j.1365-2222.2012.04014.x.
8
A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1.
J Clin Invest. 2012 Jan;122(1):327-36. doi: 10.1172/JCI57990. Epub 2011 Dec 12.
9
Role of neutrophils in innate immunity: a systems biology-level approach.
Wiley Interdiscip Rev Syst Biol Med. 2009 Nov-Dec;1(3):309-333. doi: 10.1002/wsbm.32.
10
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues.
Blood. 2008 Jul 15;112(2):256-63. doi: 10.1182/blood-2007-10-118497. Epub 2008 Mar 17.
Zotero 插件